Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Mitochondria

Mitochondria

Mitochondria are eukaryotic cellular organelles that are known to produce energy through a process called oxidative phosphorylation. Besides their primary function, mitochondria are involved in various cellular processes, including cell growth, differentiation, signaling, metabolism, and senescence. Age-related changes cause a decline in mitochondrial quality and integrity due to increased mitochondrial mutations and oxidative damage. Thus, aging can severely impact mitochondrial functions,...

Electron Transport Chain: Complex I and II

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Alzheimer Disease l: Introduction

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...

Alzheimer Disease ll: Pathophysiology

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The development and evolution of the Irish Hip Fracture Database: a quality care initiative 2013-2024.

Archives of osteoporosis·2026

Same author

Facilitators and barriers to attending postpartum screening in women with a recent pregnancy complicated by gestational diabetes mellitus: a qualitative study.

Public health·2023

Same author

Correction: Targeted gene correction in the mdx mouse using short DNA fragments: towards application with bone marrow-derived cells for autologous remodeling of dystrophic muscle.

Gene therapy·2021

Same author

'A melting pot of cultures' -challenges in social adaptation and interactions amongst international medical students.

BMC medical education·2019

Same author

A Cross-Sectional Study of Antibiotic Prescribing for Childhood Upper Respiratory Tract Infections in Irish General Practice

Irish medical journal·2018

Same author

The creative turn in evidence for public health: community and arts-based methodologies.

Journal of public health (Oxford, England)·2018

Search research articles

Related Experiment Video

Updated: Jul 12, 2026

Interactions with and Membrane Permeabilization of Brain Mitochondria by Amyloid Fibrils

Interactions with and Membrane Permeabilization of Brain Mitochondria by Amyloid Fibrils

Published on: September 28, 2019

Mitochondrial function and alzheimer's disease.

J Ojaimi¹, E Byrne

¹Department of Neurology, Columbia University, New York, N.Y. 10032, USA. joj5@columbia.edu

Biological Signals and Receptors

|May 15, 2001

Summary

Mitochondrial oxidative phosphorylation (OXPHOS) defects in Alzheimer's disease (AD) brains are linked to reduced mitochondrial number, not specific enzyme issues. These changes may reflect a global decline in brain mitochondrial activity.

Area of Science:

Neuroscience
Mitochondrial Biology
Aging Research

Background:

The brain relies heavily on aerobic metabolism, making mitochondrial function crucial for neuronal integrity.
Defects in mitochondrial oxidative phosphorylation (OXPHOS) are observed in aging brain tissue.
Previous findings suggest OXPHOS defects in Alzheimer's disease (AD) brains, but the cause remains unclear.

Purpose of the Study:

To investigate the cause of observed OXPHOS defects in Alzheimer's disease (AD) brains.
To determine if mitochondrial DNA mutations or a global decline in mitochondrial activity underlies these defects.

Main Methods:

Analysis of mitochondrial oxidative phosphorylation (OXPHOS) pathway components in aging human brain tissue.
Assessment of cytochrome c oxidase activity and mitochondrial number in Alzheimer's disease (AD) brains.

More Related Videos

Assessing Mitochondrial Function in Sciatic Nerve by High-Resolution Respirometry

Assessing Mitochondrial Function in Sciatic Nerve by High-Resolution Respirometry

Published on: May 5, 2022

Using Live Cell STED Imaging to Visualize Mitochondrial Inner Membrane Ultrastructure in Neuronal Cell Models

Using Live Cell STED Imaging to Visualize Mitochondrial Inner Membrane Ultrastructure in Neuronal Cell Models

Published on: June 30, 2023

Related Experiment Videos

Last Updated: Jul 12, 2026

Interactions with and Membrane Permeabilization of Brain Mitochondria by Amyloid Fibrils

Interactions with and Membrane Permeabilization of Brain Mitochondria by Amyloid Fibrils

Published on: September 28, 2019

Assessing Mitochondrial Function in Sciatic Nerve by High-Resolution Respirometry

Assessing Mitochondrial Function in Sciatic Nerve by High-Resolution Respirometry

Published on: May 5, 2022

Using Live Cell STED Imaging to Visualize Mitochondrial Inner Membrane Ultrastructure in Neuronal Cell Models

Using Live Cell STED Imaging to Visualize Mitochondrial Inner Membrane Ultrastructure in Neuronal Cell Models

Published on: June 30, 2023

Main Results:

Observed OXPHOS defects in AD brains, particularly reduced cytochrome c oxidase activity, are unlikely due to specific enzyme dysfunction.
The decline in cytochrome c oxidase activity correlates with a global decrease in mitochondrial number, indicating reduced overall mitochondrial activity.
The precise position of these mitochondrial changes within the Alzheimer's disease cascade is not yet definitively established.

Conclusions:

The mitochondrial dysfunction in Alzheimer's disease (AD) appears to stem from a reduction in mitochondrial number rather than specific enzyme defects.
Factors such as compromised mitochondrial transport, regulatory feedback mechanisms, and complex assembly may contribute to altered OXPHOS function in AD.